Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males

Summary

This is a first-in-human study of GSI-136, a gamma-secretase inhibitor being developed for the treatment of Alzheimer disease. This study will take place in Japan only and will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSI-136 after administration of ascending single oral doses to healthy Japanese male subjects and healthy Japanese elderly male subjects.

Timeline

Start

2008-03

Primary completion

2008-08

Completion

2008-08

Drugs

Indications